Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 56 points (-0.3%) at 15,939 as of Wednesday, Feb. 12, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,598 issues advancing vs. 1,323 declining with 154 unchanged. The Drugs industry currently sits down 0.2% versus the S&P 500, which is down 0.1%. A company within the industry that fell today was Vertex Pharmaceuticals ( VRTX), up 1.2%. Top gainers within the industry include Seattle Genetics ( SGEN), up 12.6%, Incyte ( INCY), up 4.4%, Jazz Pharmaceuticals ( JAZZ), up 4.3%, Biomarin Pharmaceutical ( BMRN), up 3.3% and GlaxoSmithKline ( GSK), up 1.1%. TheStreet would like to highlight 5 stocks pushing the industry lower today: 5. Actavis ( ACT) is one of the companies pushing the Drugs industry lower today. As of noon trading, Actavis is down $1.40 (-0.7%) to $189.85 on light volume. Thus far, 479,430 shares of Actavis exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $189.21-$193.21 after having opened the day at $192.27 as compared to the previous trading day's close of $191.25. Actavis plc, an integrated specialty pharmaceutical company, develops, manufactures, markets, and distributes pharmaceutical products in the United States, Canada, and internationally. Actavis has a market cap of $32.9 billion and is part of the health care sector. Shares are up 13.8% year-to-date as of the close of trading on Tuesday. Currently there are 11 analysts that rate Actavis a buy, no analysts rate it a sell, and 1 rates it a hold. TheStreet Ratings rates Actavis as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, generally higher debt management risk and disappointing return on equity. Get the full Actavis Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.